Home / Guides / Medications
Medications

GLP-1s for Teens: FDA Approvals, Safety, and What Parents Should Know

Wegovy and Zepbound are now approved for adolescents 12 and older. Here's what the clinical trials showed, what parents should consider, and how pediatric treatment works in practice.

Published May 6, 2026 · 15 min read
Last reviewed: May 6, 2026 by our editorial team. See our editorial process.

Bottom line

GLP-1 medications are no longer adults-only. Wegovy (semaglutide) received FDA approval for adolescents aged 12 and older in late 2022, and Zepbound (tirzepatide) followed with its own adolescent approval in 2024–2025. Clinical trial data in teens shows substantial weight loss — 16.1% with semaglutide versus 0.6% with placebo in the STEP TEENS trial — with a safety profile similar to what's seen in adults.

This is a significant shift in pediatric obesity medicine. The American Academy of Pediatrics (AAP) now explicitly recommends pharmacotherapy for adolescents with obesity, and the clinical evidence supports that position. But these are powerful medications being given to growing bodies, and parents have legitimate questions that deserve honest answers.

If you're considering a GLP-1 for your teenager, the most important step is finding a prescriber experienced in pediatric obesity medicine. This is not a decision to make through a telehealth mill. Consult a pediatric obesity specialist or an adolescent medicine physician who can evaluate the full picture.

FDA approval status

Wegovy (semaglutide 2.4 mg)

Approved by the FDA in December 2022 for chronic weight management in patients aged 12 years and older with:

This was based on the STEP TEENS trial data. The approval covers the same dosing regimen as adults, with the same titration schedule.

Zepbound (tirzepatide)

Approved in 2024–2025 for patients aged 12 and older with obesity. The approval was based on pediatric trial data showing weight loss in adolescents that was consistent with — and in some analyses, exceeded — adult results.

What's not approved for teens

Ozempic and Mounjaro are approved only for type 2 diabetes (in adults). They are not FDA-approved for weight management in adolescents, though some prescribers use them off-label. Compounded semaglutide and tirzepatide have no pediatric approval and carry additional regulatory uncertainty.

[drug:wegovy] [drug:zepbound]

What the clinical trials showed

STEP TEENS (semaglutide)

The STEP TEENS trial enrolled 201 adolescents aged 12–17 with obesity (BMI at or above the 95th percentile) or overweight (BMI at or above the 85th percentile) with at least one weight-related comorbidity. All participants received lifestyle counseling. They were randomized 2:1 to semaglutide 2.4 mg weekly or placebo for 68 weeks.

Key results:

To put that in perspective: a 15-year-old with a starting BMI of 35 on semaglutide would, on average, see their BMI drop to about 29.4 over 68 weeks. That represents a clinically meaningful shift — often enough to move a teen from class II obesity down to the overweight category.

Weight loss thresholds achieved:

Safety findings in adolescents:

Tirzepatide adolescent data

Pediatric trial results for tirzepatide showed similar patterns: significant BMI reduction in the 12–17 age group, GI side effects as the primary tolerability issue, and no unique pediatric safety concerns. The magnitude of weight loss tracked closely with adult trials, with some analyses suggesting slightly greater BMI reduction in adolescents — possibly because adolescent metabolism and hormonal environment respond robustly to GLP-1/GIP agonism.

Growth and development considerations

This is where parental concern is most warranted — and most reasonable. These medications are being given during a critical developmental window.

Height and linear growth

The available trial data (68–72 weeks) has not shown interference with linear growth in adolescents aged 12–17. Participants in the semaglutide trials continued to grow in height at rates consistent with their age and Tanner stage.

However, 68 weeks of data is a relatively short window when you're talking about growth that continues until ages 16–18 (or later for some boys). Longer-term data from extension studies and post-marketing surveillance will be important to watch.

What prescribers monitor: height velocity on growth charts at every visit, comparison with prior growth trajectory, and investigation if growth rate slows significantly.

Bone density

Rapid weight loss in adolescents raises concerns about bone mineral density, which is still accruing during the teenage years and reaches peak bone mass in the early-to-mid twenties. Adequate calcium and vitamin D intake become especially important during GLP-1 therapy.

The trial data has not shown significant bone density problems, but bone densitometry (DEXA scans) wasn't a primary endpoint. Prescribers experienced in pediatric obesity typically monitor bone health markers and ensure nutritional adequacy.

Puberty timing

Obesity itself can accelerate puberty in girls (earlier menarche) and delay it in boys. Weight loss may shift these timelines. There's no evidence that GLP-1 medications directly affect pubertal hormones, but the indirect effects of weight normalization on pubertal development are worth monitoring.

Body composition

One concern with any weight-loss intervention in adolescents is the ratio of fat loss to lean mass loss. Teens need adequate protein and resistance exercise to preserve muscle mass during weight loss. GLP-1-mediated appetite suppression can make it harder to hit protein targets, so dietary guidance is especially important in this population.

Psychological impact: obesity vs. medication

This is the conversation that often gets shortchanged.

Adolescent obesity carries well-documented psychological costs: higher rates of depression, anxiety, social isolation, bullying, disordered eating, and lower academic engagement. These are not minor quality-of-life issues — they are serious mental health consequences that track into adulthood.

The psychological impact of untreated obesity in adolescence must be weighed against the potential psychological effects of medication. These include:

Potential benefits:

Potential concerns:

A skilled pediatric obesity specialist will assess mental health as part of the intake and monitor throughout treatment. If your teen has an active eating disorder, GLP-1 therapy may not be appropriate — or may require concurrent eating disorder treatment.

Family-based lifestyle intervention

GLP-1 medications work best when embedded in a comprehensive family-based approach. Family-based means exactly what it sounds like — the whole household changes, not just the teenager.

What this looks like in practice:

The clinical evidence consistently shows that family-based behavioral interventions produce better outcomes than individual counseling for adolescents. When you add pharmacotherapy on top of that foundation, the results are substantially better than medication alone.

This is not about blame or suggesting the family caused the obesity. It's about recognizing that a teenager's food and activity environment is largely shaped by their household, and lasting change requires environmental change.

Insurance coverage

Insurance coverage for pediatric obesity treatment has improved significantly since the AAP's 2023 clinical practice guideline explicitly recommended pharmacotherapy. Key developments:

Cost without insurance: Wegovy at full retail runs roughly $1,300–$1,400/month. Zepbound is comparable. Very few families can sustain that out-of-pocket, which makes insurance navigation critical. Some programs offer copay assistance for commercially insured patients.

[program:mochi-health]

Dosing for adolescents

The dosing for adolescents is the same as for adults. For Wegovy:

| Week | Dose | Frequency | |---|---|---| | Weeks 1–4 | 0.25 mg | Once weekly | | Weeks 5–8 | 0.5 mg | Once weekly | | Weeks 9–12 | 1.0 mg | Once weekly | | Weeks 13–16 | 1.7 mg | Once weekly | | Week 17 onward | 2.4 mg | Once weekly |

The titration schedule exists to minimize GI side effects. Some prescribers extend the titration (spending more time at lower doses) for teens who are particularly sensitive to nausea, which is a reasonable clinical decision.

For Zepbound, the titration follows a similar escalation pattern from 2.5 mg up to 10 or 15 mg weekly.

Monitoring requirements

Adolescents on GLP-1s need more active monitoring than adults, reflecting the developmental context.

At every visit (typically monthly during titration, every 2–3 months at maintenance):

Periodic labs:

Additional monitoring as indicated:

When to start medication vs. lifestyle only

The AAP's 2023 clinical practice guideline provides a framework:

The key word is offered — not mandated. The AAP's position is that withholding effective pharmacotherapy from adolescents with obesity, when the clinical evidence supports it, is not in the patient's best interest. But the decision is collaborative: prescriber, parent, and teenager all participate.

When medication is more likely appropriate:

When a lifestyle-first approach may be preferred:

Common parental concerns — addressed honestly

"We don't know the long-term effects."

This is true. We have 68–72 weeks of randomized trial data in adolescents, plus ongoing extension studies and post-marketing surveillance. That's a meaningful evidence base, but it's not 10-year safety data.

The honest framing: we know the long-term effects of untreated adolescent obesity very well — they include type 2 diabetes, cardiovascular disease, fatty liver disease progressing to cirrhosis, joint damage, sleep apnea, and mental health consequences. The known harms of untreated obesity must be weighed against the unknown long-term effects of medication.

"Will my teen become dependent on the medication?"

GLP-1s are not addictive. But weight regain after discontinuation is common — in both adolescents and adults. This isn't dependency in the addiction sense. It reflects the biology of obesity: the hormonal and neural signals that drive appetite and body weight set-point return to their baseline state when the medication is removed.

Whether your teen will need to stay on medication long-term, transition off after adolescence, or use it cyclically is a clinical decision that will evolve over time. There's no single right answer, and your prescriber should discuss realistic expectations.

"What about body image?"

Medication can be part of a healthy body image framework or it can undermine it — context matters. If the message is "your body is broken and needs drugs to fix it," that's harmful. If the message is "your body's appetite signals aren't well-calibrated right now, and this medication helps reset them while we build healthier habits together," that's a very different framing.

A skilled pediatric obesity specialist will navigate this carefully. If your teen is struggling with body image, eating disorder screening should happen before medication starts.

"Are we taking the easy way out?"

No. GLP-1 therapy for adolescent obesity is evidence-based medicine, not a shortcut. The medications are most effective when combined with comprehensive lifestyle changes — which require real effort from the entire family. If anything, families engaged in GLP-1 therapy are typically doing more, not less, than families trying lifestyle intervention alone.

Nutritional requirements during growth

Adolescent nutritional needs are higher than adult needs because of ongoing growth. GLP-1-related appetite suppression can make it harder for teens to meet these requirements.

Key nutritional priorities:

A registered dietitian experienced in both pediatric nutrition and obesity management is an invaluable member of the care team. If your teen's program doesn't include dietitian access, consider adding one.

The role of pediatric obesity medicine specialists

General pediatricians are increasingly comfortable prescribing GLP-1s for adolescent obesity, but a pediatric obesity medicine specialist brings deeper expertise in:

The Obesity Medicine Association and the AAP maintain directories of board-certified obesity medicine specialists. If your area doesn't have one, some programs offer virtual consultations.

Practical guidance for families

1. Start with the right prescriber. A pediatrician or adolescent medicine specialist experienced in obesity management, not a telehealth service optimized for speed. 2. Make it a family project. The dietary and activity changes should apply to the whole household. 3. Prioritize protein and hydration. These are the two nutritional areas most likely to fall short with appetite suppression. 4. Expect GI side effects during titration. Nausea is common and usually temporary. Have a plan for managing it (smaller meals, bland foods, ginger). 5. Monitor school impact. If nausea or other side effects are affecting school attendance or performance, your prescriber can slow the titration. 6. Talk about it openly. Your teen should understand what the medication does, why they're taking it, and that it's not a reflection of personal failure. 7. Screen for eating disorders. Before starting and periodically during treatment. GLP-1s and active eating disorders are a combination that requires specialist management. 8. Plan for the long term. Discuss with your prescriber what happens after 6 months, after a year, and as your teen transitions to adult care.

[guide:finding-a-prescriber]

GLP-1 therapy for adolescent obesity is a legitimate, evidence-based treatment option that the medical community now endorses. But it works best as part of a comprehensive, family-centered approach guided by an experienced prescriber who understands the unique needs of growing bodies and developing minds. Consult a pediatric obesity specialist to determine whether this is the right path for your teenager.